Date: 2015-12-02
Type of information: Nomination
Compound:
Company: Auspherix (Australia) Auspherix Limited (UK)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 2, 2015, Auspherix Limited (UK), an early stage anti-infectives company, has announced the appointment of Dr. Neil Miller as its Chief Scientific Officer, effective 1 December. As CSO, Dr Miller will take full responsibility for driving forward the Company’s antibiotic R&D programmes, both in house and through partners, into clinical Proof-of-Concept studies. The Company’s discovery platform has led to the invention of novel compound series with activity against both gram-positive and gram-negative bacteria. Prior to joining Auspherix, Dr Miller has spent two decades in the pharmaceutical industry at GSK, most recently as Senior Director and Head of Chemistry, DMPK & External Discovery in Singapore. In this role he led a research collaboration with the National University of Singapore, to evaluate monoclonal antibodies for the potential treatment of Dengue Fever. Dr Miller has held a variety of managerial and scientific roles at GSK, including that of Site Head at GSK’s R&D Centre in Singapore. He has a degree in Chemistry with Pharmacology and a PhD in Organic Synthesis from the University of Liverpool, UK. Dr Miller replaces Professor Ian Charles, co-founder and previously consultant Chief Scientific Officer, who will continue to actively contribute to the Company’s scientific direction as both a member of the Board and as Chair of the Scientific Advisory Board. Auspherix is expanding its UK-based microbiology and management teams at the Stevenage Bioscience Catalyst and is intensifying its discovery research, and intends to explore further the potential in its antibiotic platform.
Financial terms:
Latest news:
